<code id='D20FAC7439'></code><style id='D20FAC7439'></style>
    • <acronym id='D20FAC7439'></acronym>
      <center id='D20FAC7439'><center id='D20FAC7439'><tfoot id='D20FAC7439'></tfoot></center><abbr id='D20FAC7439'><dir id='D20FAC7439'><tfoot id='D20FAC7439'></tfoot><noframes id='D20FAC7439'>

    • <optgroup id='D20FAC7439'><strike id='D20FAC7439'><sup id='D20FAC7439'></sup></strike><code id='D20FAC7439'></code></optgroup>
        1. <b id='D20FAC7439'><label id='D20FAC7439'><select id='D20FAC7439'><dt id='D20FAC7439'><span id='D20FAC7439'></span></dt></select></label></b><u id='D20FAC7439'></u>
          <i id='D20FAC7439'><strike id='D20FAC7439'><tt id='D20FAC7439'><pre id='D20FAC7439'></pre></tt></strike></i>

          Home / knowledge / leisure time

          leisure time


          leisure time

          author:leisure time    Page View:29512
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In